Old versus new antiepileptic drugs: the SANAD study

Lancet

Volumn 370, Issue 9584, 2007, Pages 315-

  Hadžić, Nedim ^a   Vara, Roshni ^a   Raiman, Julian ^a   Mieli Vergani, Giorgina ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID;

ALPERS DISEASE; ANTICONVULSANT THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; HUMAN; LETTER; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; PRIORITY JOURNAL; SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34447625364     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61153-2     Document Type: Letter

References (5)

1. Marson A., Al-Kharusi A., Alwaidh M., et al., on behalf of the SANAD Study Group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised trial. Lancet 369 (2007) 1016-1026
2. Le Bihan G., Bourreille J., Sampson M., Leroy J., Szekely A., and Coquerel A. Fatal hepatic failure and sodium valproate. Lancet 2 (1980) 1298-1299
3. Chabrol B., Mansini J., Chretien D., Rustin P., Munnich A., and Pinsard N. Valproate-induced hepatic failure in a case of cytochrome C oxidase deficiency. Eur J Pediatr 153 (1994) 133-135
4. Raiman J., Champion M., Baker A., Dhawan A., Mieli-Vergani G., and Hadzic N. Outcome of mitochondrial cytopathies presenting with liver involvement (abstract). J Pediatr Gastroenterol Nutr 40 (2005) 622
5. Thomson M., Lynch S., Strong R., Shepherd R., and Marsh W. Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure: a need for critical risk-benefit appraisal in the use of valproate. Transplant Proc 32 (2000) 200-203